FilingsTodayWonbiogen
At a glance
Wonbiogen filed 18 disclosures in the last 12 months, including 1 buyback. The most recent key filing was on Dec 8.
Revenue for 2025 was ₩35.2B, up 15.8% on 2024. Operating margin was 22.5% against 21% a year earlier. Debt was 12% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩19.2B and operating profit of ₩4.9B.
The 2025 annual report lists 77 employees with an average tenure of 4 years. Its 4 directors and auditors were paid ₩211.2M each on average. It paid ₩140 per common share in cash dividends, against ₩20 a year earlier (+600%). 김원일 and related parties held 32.35% at year end.
From the 2025 annual report
Staff: 77 (45 men, 32 women), of whom 0 on fixed-term contracts. Directors and auditors: 4, paid ₩844.8M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩140 | ₩20 | ₩10 |
| Payout ratio | 15.3% | 12.5% | 12.9% |
| Yield (as filed) | 2.23% | 1.81% | 1.32% |
| Total cash dividends | ₩985M | ₩709M | ₩709M |
Largest shareholder
김원일 holds 32.35%; with 0 related parties the group holds 32.35% of common shares at year end (from 31.05% at the start of the year).
Individuals paid ₩500M or more
| 김원일 대표이사 | ₩618.8M |
Auditor: 정진세림 회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.